| gap-pubmed-20260410- | What accounts for differential dazucorilant efficacy between slowly vs aggressiv | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does selective GR modulation with dazucorilant differentially affect amyloid | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do GLP-1 agonists provide neuroprotection in non-diabetic patients with neurodeg | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific central mechanisms by which GLP-1 receptor agonists affect | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do GLP-1 agonists improve brain biomarkers but not cognitive scores in neuro | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does EGCG treatment lead to increased levels of the mature 60 kDa ADAM10 pro | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanism causes EGCG to specifically activate ADAM10 but not ADA | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms allow TNFα to regulate both Dnmt1 and Ucp1 expression in adipose | open | 0.75 | 0.00 | 2026-04-10 | 0 | | metabolic-neuroscience |
| gap-pubmed-20260410- | How does TNFα mediate anorectic effects in the hypothalamus to produce NP-1-indu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroendocrinology |
| gap-pubmed-20260410- | What is the temporal relationship between Nrf2 activation and Wnt3a/β-catenin si | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does oxytocin receptor binding specifically inhibit DNMT1-MeCP2 interaction | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do ABI3 and PLCG2 variant effects replicate in larger cohorts of non-Alzheimer n | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the functional mechanisms by which ABI3 and PLCG2 variants alter microg | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does PLCG2_rs72824905-G show opposite effects in amyloid-β diseases vs. prim | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does Clostridia_UCG-014 abundance relate to amyloid cascade progression in A | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific mechanisms through which gut bacteria influence brain path | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do gastrosomes represent a conserved organelle across species and microglial act | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do TREM2 and SLC37A2 mechanistically regulate gastrosome size and function? | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms regulate gastrosome formation and lipid processing wit | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What is the relationship between PINK1/Parkin downregulation and Nrf2/UCP2 pathw | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does PCSK9 directly cause mitochondrial oxidative damage in endothelial cell | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the selectivity of baicalein for MAPK1 versus other MAPK family | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does hsa-miR-5692a mechanistically regulate EP300, MAPK1, and CREBBP in PD p | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What causes the disruption of global O-GlcNAc modification in Alzheimer's diseas | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does O-GlcNAc modification mechanistically regulate PINK1-dependent mitophag | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What causes the age-related decline in autophagy-related gene expression in neur | open | 0.74 | 0.00 | 2026-04-10 | 0 | | aging |
| gap-pubmed-20260410- | How does rapamycin-induced autophagy activation translate to improved cognitive | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which autophagy regulates NPC prol | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurogenesis |
| gap-pubmed-20260410- | What molecular mechanisms allow chaperones to prevent neurodegeneration across d | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do misfolded monomers and oligomeric intermediates cause neuronal toxicity? | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether protein aggregates are protective versus toxic in neurod | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does the CaMKII/CaN switch mechanism operate in axon regeneration after injury? | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neuroregeneration |
| gap-pubmed-20260410- | How do different calcium signal amplitudes selectively activate CaMKII versus Ca | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | cellular-neuroscience |
| gap-pubmed-20260410- | What are the molecular mechanisms downstream of CaMKII/CaN-PP1 that execute attr | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | developmental-neuroscience |
| gap-pubmed-20260410- | Why is FGF21 expression specifically downregulated during intervertebral disc de | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does FGF21 specifically upregulate SIRT1 expression in nucleus pulposus cell | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do small GTPases regulate tau clearance pathways similarly to their established | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do tau aggregates spread from nerve cells and what role do small GTPases pla | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific mechanisms by which small GTPases regulate tau protein pho | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which senolytic or senomorphic approaches are most effective for post-stroke bra | resolved | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do senescent cells spread from the ischemic core to the broader ipsilateral | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific mechanisms drive the transition from acute ischemic injury to stre | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does route of administration fundamentally alter olanzapine's metabolic effe | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neuropsychopharmacology |
| gap-pubmed-20260410- | What causes the paradoxical ATP depletion and starvation-like metabolic signatur | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurometabolism |
| gap-pubmed-20260410- | How does hypothalamic JNK1 activation signal through the vagus nerve to upregula | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurometabolism |
| gap-pubmed-20260410- | What is the temporal relationship between PI3K/Akt activation and downstream neu | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does dual GLP-1/GIP agonism provide superior neuroprotection compared to sin | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroprotection |
| gap-pubmed-20260410- | How do mitochondrial fusion/fission dynamics, biogenesis, and mitophagy differen | open | 0.53 | 0.00 | 2026-04-10 | 0 | | mitochondrial-biology |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which mitochondrial dysfunction di | open | 0.60 | 0.00 | 2026-04-10 | 0 | | cellular-metabolism |
| gap-pubmed-20260410- | Does disrupted temperature-ROS signaling contribute to circadian dysfunction in | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |